Drug Profile
QBECO - Qu Biologics
Alternative Names: QBECO SSILatest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Qu Biologics
- Class Antineoplastics; Bacterial vaccines; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer; Crohn's disease; Ulcerative colitis
- Phase I Ovarian cancer; Pancreatic cancer
Most Recent Events
- 03 Jan 2024 Phase-I clinical trials in Ovarian cancer in Canada (SC), prior to January 2024 (Qu Biologics pipeline, January 2024)
- 03 Jan 2024 Phase-I clinical trials in Pancreatic cancer in Canada (SC), prior to January 2024 (Qu Biologics pipeline, January 2024)
- 30 Aug 2023 Phase-II clinical trials in Colorectal cancer (Metastatic disease) in Canada (SC) (NCT05677113)